ArticleMethods in molecular biology (Clifton, N.J.)2025
Probing Antibody Binding Sites on G Protein-Coupled Receptors Using Genetically Encoded Photo-Activatable Cross-Linkers.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe a methodology to map epitopes of monoclonal antibodies (mAbs) that bind to G protein-coupled receptors (GPCRs). The method involves using genetic code expansion technology to introduce a non-canonical amino acid (ncAA) residue into an expressed GPCR that can serve as a photo-activatable cross-linkers in mammalian cells in culture. Interaction sites between the engineered receptor variants and the cognate mAb are mapped by determining which of the p-azido-L-phenylalanine (azF) or p-benzoyl-L-phenylalanine (BzF) residues cross-link to the mAb upon ultraviolet (UV) irradiation. These sites are compared with the sites of amino acid replacements that cause loss of mAb binding to create a surface binding map of the mAb epitope. The precision of the GPCR-mAb binding-site map is dependent on the number of receptor mutants studied and the availability of a high-resolution three-dimensional structural models. One advantage of the method is that anti-receptor mAbs with discontinuous epitopes may also be elucidated. In addition, the method is also applicable to map the cell-surface epitopes of mAbs targeting proteins other than GPCRs.
Indexed as
Identifiers
40593422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.